This article first appeared on GuruFocus.
Johnson & Johnson (NYSE:JNJ), the healthcare heavyweight behind blockbuster medicines and medical technologies, surged approximately 3% to $270.19 Tuesday morning as investors rotated out of high-growth technology stocks and into defensive companies. While the Nasdaq struggled with broad selling pressure, J&J pushed toward fresh 52-week highs as investors rewarded stability.
The move comes as Johnson & Johnson continues to prove that size can still deliver growth. Second-quarter sales climbed 6.6% to $25.31 billion, while adjusted earnings reached $2.90 per share. Management also raised its 2026 outlook, targeting approximately $101.1 billion in revenue and $11.68 in adjusted earnings per share at the midpoint. The company is now approaching a milestone few healthcare giants reach: surpassing $100 billion in annual sales.
Johnson & Johnson Stock Jumps 3% as Healthcare Rotation Lifts Shares ยท us.finance.gurufocus
But investors are paying a premium for that consistency. The GF Value chart shows J&J trading at $271.19 versus an estimated fair value of $192.38, meaning the stock sits roughly 41% above its GF Value. The market is clearly pricing in strong execution from its pharmaceutical pipeline, medical-device portfolio, and decades-long dividend record.
The question is no longer whether Johnson & Johnson is a quality businessit clearly is. The bigger question is whether future growth can justify today’s valuation. With expectations already elevated, J&J will need continued pipeline wins, expanding earnings, and stronger innovation to keep investors chasing the stock after this defensive rally.